PEPT / REX ETF Trust - REX Peptide ETF - SEC-Einreichungen, Geschäftsbericht, Stimmrechtsmitteilung

September 4, 2026

Exhibit 16.1 September 4, 2026 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Commissioners: We have read the statements made by Regenerex Pharma, Inc. (the “Company”), which we understand will be filed with the Securities and Exchange Commission. Pursuant to Item 4.01 of Form 8-K filed by the Company and dated September 4, 2026, we are in agreement with the statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2026 REGENEREX PHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2026 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2026 REGENEREX PHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2026 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KT [ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year Ended ____ [X] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KT [ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year Ended OR [X] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from April 1, 2025 to December 31, 2025 Commission File Number : 000-53230 REGENEREX PH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2026 REGENEREX PHARMA, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2026 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

IN THE CHANCERY COURT FOR SMITH COUNTY, TENNESSEE, AT CARTHAGE

IN THE CHANCERY COURT FOR SMITH COUNTY, TENNESSEE, AT CARTHAGE REGENEREX PHARMA, INC.

IN THE CHANCERY COURT FOR SMITH COUNTY, TENNESSEE, AT CARTHAGE

IN THE CHANCERY COURT FOR SMITH COUNTY, TENNESSEE, AT CARTHAGE REGENEREX PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2026 REGENEREX PHARMA, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2026 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 REGENEREX PHARMA, INC (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 REGENEREX PHARMA, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

(Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: December 31, 2025 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-53230 CUSIP NUMBER 682738 10 9 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: December 31, 2025 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Rep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 [ ] TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

(Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: September 30, 2025 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-53230 CUSIP NUMBER 682738 10 9 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: September 30, 2025 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 REGENEREX PHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 REGENEREX PHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 [ ] TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified in i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 REGENEREX PHARMA, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 REGENEREX PHARMA, INC (Exact Name of Registrant as Specified in its Charter) Nevada 000-53230 98-0479983 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2025 [ ] TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2025 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number : 000-53230 REGENEREX PHARM

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 31, 2025 REGENEREX PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 000-53230 98-0479983 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identifica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 [ ] TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 10, 2024 REGENEREX PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 000-53230 98-0479983 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 [ ] TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 [ ] TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified in i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2024 [ ] TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2024 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number : 000-53230 REGENEREX PHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 [ ] TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 [ ] TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 REGENEREX PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 000-53230 98-0479983 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 [ ] TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified in i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2023 [ ] TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2023 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number : 000-53230 REGENEREX PHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 [ ] TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 [ ] TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 25, 2022 REGENEREX PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 000-53230 32-0535345 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identific

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 [ ] TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified in i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2022 [ ] TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2022 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number: 000-53230 REGENEREX PHARMA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 [ ] TRANS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 [ ] TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 REGENEREX PHARMA, INC. (Exact name of registrant as specified

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 14, 2022 REGENEREX PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 000-53230 98-0479983 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identifi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [] Preliminary Information Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14c‑5(d)(2)) [X] Definitive Information Statement PEPTIDE TECHNOLOGIES, INC. (Name of Registra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

PRE 14C 1 pre14c.htm PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14c‑5(d)(2)) [] Definitive Information

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-53230 98-0479983 (State or other jurisdiction of incorporation) (Commiss

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-53230 98-0479983 (State or other jurisdiction of incorporation) (Commiss

Asset Purchase Agreement Dated November 15, 2021

EX-10.1 2 exhibit10-1.htm ASSET PURCHASE AGREEMENT DATED NOVEMBER 15, 2021 ASSET PURCHASE AGREEMENT DATED AS OF November 15, 2021 BY AND AMONG peptide technologies inc AND DEBORAH L. AND GREGORY P. PILANT ASSET PURCHASE AGREEMENT This Asset Purchase Agreement, dated as of November 15, 2021 (the “Agreement”), is by and among PEPTIDE TECHNOLGIES INC. Corp, a Nevada Corporation (referred to as “PEPT”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 [ ] TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as speci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 [ ] TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2021 ( ) TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2021 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number: 000-53230 PEPTIDE TECHNOLO

Quarterly Report - QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2020

10-Q 1 form10q.htm QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File N

Quarterly Report - QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as speci

Quarterly Report - QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified

Annual Report - AMENDMENT NO. 1 TO THE ANNUAL REPORT

10-K/A 1 form10ka.htm AMENDMENT NO. 1 TO THE ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2020 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans

Annual Report - ANNUAL REPORT FOR THE FISCAL YEAR ENDED MARCH 31, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2020 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number: 000-53230 PEPTIDE TECHNOLO

PEPT / Peptide Technologies, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specif

PEPT / Peptide Technologies, Inc. TEXT-EXTRACT - -

January 27, 2020 Irene Getty Chief Financial Officer Peptide Technologies, Inc. 5348 Vegas Drive #177 Las Vegas, NV 89108 Re: Peptide Technologies, Inc. Form 10-K for Fiscal Year Ended March 31, 2019 Filed June 24, 2019 File No. 000-53230 Dear Ms. Getty: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of t

LETTER

January 27, 2020 Irene Getty Chief Financial Officer Peptide Technologies, Inc. 5348 Vegas Drive #177 Las Vegas, NV 89108 Re: Peptide Technologies, Inc. Form 10-K for Fiscal Year Ended March 31, 2019 Filed June 24, 2019 File No. 000-53230 Dear Ms. Getty: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2019 ( ) TRANSITION REP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2019 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number: 000-53

Peptide Technologies Inc. (dba Eternelle Skincare Products) 5348 Vegas Drive, Suite 177 Las Vegas, NV 98108-2347 Phone: 702.805.7525

Peptide Technologies Inc. (dba Eternelle Skincare Products) 5348 Vegas Drive, Suite 177 Las Vegas, NV 98108-2347 Phone: 702.805.7525 January 23, 2020 United States Security and Exchange Commission Washington, DC 20549 Re: Peptide Technologies, Inc. Form 10-K for the Fiscal Year Ended March 31, 2019 Filed June 24, 2019 File No. 000-53230 Dear Ms. Mariner: You requested that we amend our Form 10-K t

LETTER

January 14, 2020 Irene Getty Chief Financial Officer Peptide Technologies, Inc. 5348 Vegas Drive #177 Las Vegas, NV 89108 Re: Peptide Technologies, Inc. Form 10-K for the Fiscal Year Ended March 31, 2019 Filed June 24, 2019 File No. 000-53230 Dear Ms. Getty: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we ma

PEPT / Peptide Technologies, Inc. TEXT-EXTRACT - -

January 14, 2020 Irene Getty Chief Financial Officer Peptide Technologies, Inc. 5348 Vegas Drive #177 Las Vegas, NV 89108 Re: Peptide Technologies, Inc. Form 10-K for the Fiscal Year Ended March 31, 2019 Filed June 24, 2019 File No. 000-53230 Dear Ms. Getty: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we ma

PEPT / Peptide Technologies, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as speci

PEPT / Peptide Technologies, Inc. 10-Q/A - Quarterly Report - AMENDMENT NO. 1 TO THE QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Amendment No. 1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of reg

PEPT / Peptide Technologies, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified

PEPT / Peptide Technologies, Inc. 10-K - Annual Report - ANNUAL REPORT FOR THE FISCAL YEAR ENDED MARCH 31, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number: 000-53230 PEPTIDE TECHNOLO

PEPT / Peptide Technologies, Inc. QUARTERLY RE PORT FOR THE PERIOD ENDED DECEMBER 31, 2018 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY RE PORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Name of small business issuer as

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 3, 2018 Commission File Number 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 State or other jurisdiction of (I.R.S. Employer incorporation or or

PEPT / Peptide Technologies, Inc. QUARTERLY REPORT FOR THE QUARTERLY ENDED SEPTEMBER 30, 2018 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as speci

PEPT / Peptide Technologies, Inc. QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2018 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specifed i

PEPT / Peptide Technologies, Inc. ANNUAL REPORT FOR THE YEAR ENDED MARCH 31, 2018 (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2018 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission File Number: 000-53230 PEPTIDE TECHNOLO

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 10, 2018 Commission File Number 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 State or other jurisdiction of (I.R.S. Employer incorporation or orga

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 16, 2018 Commission File Number 000-53230 PEPTIDE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 State or other jurisdiction of (I.R.S. Employer incorporation or organ

PEPT / Peptide Technologies, Inc. QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2017 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 ETERNELLE SKINCARE PRODUCTS INC. (Name of small business issue

PEPT / Peptide Technologies, Inc. QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2017 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 ETERNELLE SKINCARE PRODUCTS INC. (Name of small business issu

LETTER

Mail Stop 4631 September 19, 2017 Baxter Koehn Chief Executive Officer Eternelle Skincare Products Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10/A (Amendment No. 2) GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10/A (Amendment No. 2) GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 (State or other jurisdiction of (IRS Employer incorporation or organization) I

Eternelle Skincare Products Inc. 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347

Eternelle Skincare Products Inc. 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347 September 6, 2017 Pamela A. Long Assistant Director Office of Manufacturing and Construction Division of Corporate Finance United States Securities and Exchange Commission Re: Eternelle Skincare Products Inc. Amendment No. 1 to Form 10-12G Filed August 18, 2017 File No. 000-53230 Dear Ms. Pamela Long: The Company modi

LETTER

Mail Stop 4631 September 1, 2017 Baxter Koehn Chief Executive Officer Eternelle Skincare Products Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 /A (Amendment No. 1) GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 /A (Amendment No. 1) GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 (State or other jurisdiction of (IRS Employer incorporation or organization)

Eternelle Skincare Products Inc. 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347

Eternelle Skincare Products Inc. 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347 August 18, 2017 Pamela A. Long Assistant Director Office of Manufacturing and Construction Division of Corporate Finance United States Securities and Exchange Commission Re: Eternelle Skincare Products Inc. Registration Statement on Form 10-12G Filed July 28, 2017 File No. 000-53230 Dear Ms. Pamela Long: The Company m

LETTER

Mail Stop 4631 August 11, 2017 Baxter Koehn Chief Executive Officer Eternelle Skincare Products Inc.

PEPT / Peptide Technologies, Inc. QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2017 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT Commission File No. 000-53230 ETERNELLE SKINCARE PRODUCTS INC. (Name of small business issuer as

Amended Articles of Incorporation

Articles of Incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC. (Exact name of regist

Filed by Avantafile.com - Eternelle Skincare Products Inc. - Form 10-12g UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 (State or other jurisdict

Advance from Baxter Koehn to Eternelle Skincare Products Inc.

Eternelle Skincare Products Inc. (formerly Peptide Technologies, Inc.) 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347 Re: Eternelle Skincare Products Inc. Related Party Advance From Baxter Koehn, Chief Financial Officer In early 2015, Baxter Koehn, Chief Financial Officer of Eternelle Skincare Products Inc. (the “Company”), agreed to advance to the Company the funds required to pay for operating

Corporate Bylaws

Amended Articles of Incorporation

Eternelle Skincare Products Inc. (formerly Peptide Technologies, Inc.) 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347

Filed by Avantafile.com - Eternelle Skincare Products Inc. - Response Letter Eternelle Skincare Products Inc. (formerly Peptide Technologies, Inc.) 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347 July 28, 2017 Pamela Long Assistant Director Office of Manufacturing and Construction Division of Corporate Finance United States Securities and Exchange Commission Re: Eternelle Skincare Products Inc. Re

Eternelle Skincare Products Inc. (formerly Peptide Technologies, Inc.) 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347

Eternelle Skincare Products Inc. (formerly Peptide Technologies, Inc.) 5348 Vegas Drive, #177 Las Vegas, NV 98108-2347 July 28, 2017 Pamela Long Assistant Director Office of Manufacturing and Construction Division of Corporate Finance United States Securities and Exchange Commission Re: Eternelle Skincare Products Inc. Registration Statement on Form 10-12B Filed June 23, 2017 File No. 001-38133 De

LETTER

Mail Stop 4631 July 19, 2017 Baxter Koehn Chief Financial Officer Eternelle Skincare Products Inc.

Peptide Technologies GENERAL FORM FOR REGISTRATION OF SECURITIES

Filed by Avantafile.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 (State or other jurisdiction of (IRS Employer incorporation or organizatio

Peptide Technologies 2G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRANT UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-53230 PEPTIDE TECHNOLOGIES, INC. 601 Union Street, Two Union Square, 42nd

PEPT / Peptide Technologies, Inc. 10-K - Annual Report - ANNUAL REPORT FOR THE FISCAL YEAR ENDED NOVEMBER 30, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-53230 PEPTIDE TEC

PEPT / Peptide Technologies, Inc. NT 10-K - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: November 30, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transitio

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 5, 2015 Commission File Number 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 State or other jurisdiction of (I.R.S. Employer incorporation or org

Letter of James Stafford, Inc., dated January 5, 2015.

JAMES STAFFORD James Stafford, Inc. Chartered Accountants Suite 350 – 1111 Melville Street Vancouver, British Columbia Canada V6E 3V6 Telephone +1 604 669 0711 Facsimile +1 604 669 0754 www.JamesStafford.ca 5 January 2015 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Sirs: We have read the statements, included under Item 4.01 of the Form 8-K of Peptide Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended 31 August 2014 [ ] TRANSITION REPO

10-Q 1 form10q.htm QUARTERLY REPORT FOR THE PERIOD ENDED AUGUST 31, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended 31 August 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

PEPT / Peptide Technologies, Inc. NT 10-Q - -

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number-0-27485 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR For Period Ended: August 31, 2014 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 14, 2014 Commission File Number 333-133347 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 - - State or other jurisdiction of (I.R.S. Employer incorporation o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 8, 2014 Commission File Number 333-133347 Peptide Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 98-0479983 - - State or other jurisdiction of (I.R.S. Employer incorporation or

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 28, 2014 Commission File Number 333-133347 PEPTIDE TECNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 98-0479983 - - State or other jurisdiction of (I.R.S. Employer incorporation or o

10-Q/A

10-Q/A 1 pept10qa053114.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A AMENDMENT #1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPTIDE

PEPT / Peptide Technologies, Inc. NT 10-Q - -

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number-0-27485 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR For Period Ended: May 31, 2014 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 19, 2014 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 (State or other (Commission File Number) (IRS Employer Number) jurisdiction of incorporation)

Entry into a Material Definitive Agreement

8-K 1 pept8kextofagr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 19, 2014 PEPTIDE TECHNOLOGIES, INC. - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 (State or other (Commission File Number) (IRS Employer Number) jur

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PE

-

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File No. 333-133347 Form 10-K for Period Ended: November 30, 2013 PART - I - Registrant Information PEPTIDE TECHNOLOGIES, INC. - (Exact name of registrant as specified in its charter) 601 Union Street, Two Union Square, 42nd Floor, Seattle, Washington 98101 - (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 Peptide Techno

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPT

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPTIDE

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PE

10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPTIDE

10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPTIDE TE

Entry into a Material Definitive Agreement -

UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 13, 2012 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Nevada 333-133347 98-0479983 (State or other (Commission File (IRS Employer jurisdiction of Number) Number) incorpor

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPT

EX-10

EXHIBIT 10.1 AMENDMENT TO ASSET PURCHASE AGREEMENT DATED AUGUST 23, 2011 This Amendment made this 29th day of August, 2012. Peptide Technologies Inc 601 Union Square 42nd Floor Seattle Washington 98101 WHEREAS the Purchase price of the Asset was reduced from 75,000,000 shares to 45,000,000 shares, and, NOTE: An Amendment to the Asset Purchase Agreement dated December 2011 reduced the purchase pric

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 4, 2012 PEPTIDE TECHNOLOGIES, INC. - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 (State or other (Commission File (IRS Employer jurisdiction of Number) Identification

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPTIDE

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PE

-

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number-0-27485 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR For Period Ended: February 29, 2012 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Repor

10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 PEPTIDE TE

EX-10

AMENDMENT TO ASSET PURCHASE AGREEMENT DATED AUGUST 23, 2011 This Amendment made this 14th day of December, 2011 BETWEEN PARTY A: Dr.

8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Earliest Event Reported: December 14, 2011 PEPTIDE TECHNOLOGIES, INC. - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - (State or other (Commission File (IRS Employer jurisdiction of N

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2011 PEPTIDE TECHNOLOGIES, INC. - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - (State or other jurisdiction (Commission File (IRS Employer Identifi of incorpora

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 CREE

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 3, 2011 CREENERGY CORPORATION - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - (State or other jurisdiction (Commission File (IRS Employer Identifi of incorporation)

8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Earliest Event Reported: August 23, 2011 CREENERGY CORPORATION - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - (State or other jurisdiction (Commission File (IRS Employer Identifi

EX-10

ASSET PURCHASE AGREEMENT DATED AS OF AUGUST 23rd, 2011 BY AND AMONG CREENERGY CORP.

DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Reg.ss.240.14c-101 Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [] Preliminary Information Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement CRE

EX-10

ASSET PURCHASE AGREEMENT DATED AS OF AUGUST 23rd, 2011 BY AND AMONG CREENERGY CORP.

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Earliest Event Reported: August 23, 2011 CREENERGY CORPORATION - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - (State or other jurisdiction (Commission File (IRS Employer Identifica

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 24, 2011 CREENERGY CORPORATION - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - (State or other jurisdiction (Commission File (IRS Employer of incorporation) Number) I

PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Reg.ss.240.14c-101 Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [] Definitive Information Statement CRE

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Earliest Event Reported: August 8, 2011 CREENERGY CORP. - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - (State or other jurisdiction (Commission File (IRS Employer Identi- of incorp

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 CREENER

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2011 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 CRE

10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2010 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 CREENERGY C

NT 10-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number-0-27485 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [] Form 11-K [] Form 20-F [] Form 10-Q [] Form N-SAR For Period Ended: November 30, 2010 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Repor

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 15, 2010 CREENERGY CORPORATION - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction of (Commission File (IRS Employer Identification incor

EX-16.1

EXHIBIT 16.1 SCHUMACHER & ASSOCIATES, INC. Certified Public Accountants 7931 S. Broadway, #314 Littleton, CO 80122 (303) 480-5037 FAX (303) 379-5394 November 22, 2010 United States Securities and Exchange Commission Mail Stop 11-3 450 Fifth Street, N. W. Washington, D.C. 20549 Re: Creernergy Corporation Dear Sirs/Madams: The undersigned Schumacher & Associates, Inc. previously acted as independent

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 29, 2010 CREENERGY CORPORATION - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction (Commission File (IRS Employer Identifi of incorporatio

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2010 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 CREE

NT 10-Q

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number-0-27485 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR For Period Ended: August 31, 2010 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 8, 2010 CREENERGY CORPORATION (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction of (Commission File (IRS Employer Identification incorpo

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of earliest event reported: August 18, 2010 CREENERGY CORPORATION - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction of (Commission File (IRS Employer incor

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2010 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE

NT 10-Q

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number-0-27485 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR For Period Ended: May 31, 2010 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on

LETTER

July 8, 2010 Shari Sookarookoff President and Chief Executive Officer Online Originals, Inc.

CORRESP

Online Originals, Inc. 2020 Sherwood Park, Suite 57113 AB, T8A 3H9, Canada July 7, 2010 Ms. Jan Woo Securities and Exchange Commission One Station Place 100 F Street, NE Washington DC 2549 Re: Online Originals, Inc. Preliminary Information Statement on Schedule 14C Filed June 25, 2010 File No. 000-53230 Dear Ms. Woo: In response to your comment letter dated June 28, 2010, Online Originals, Inc. ac

DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Reg.ss.240.14c-101 Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [] Preliminary Information Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement ONL

PRER14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT AMENDMENT #1 Reg.ss.240.14c-101 Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [] Definitive Information

CORRESP

Michael A. Littman Attorney at Law 7609 Ralston Road Arvada, CO 80002 (303) 422-8127 Fax (303) 431-1567 July 2, 2010 Ms. Jan Woo Securities and Exchange Commission One Station Place 100 F Street, NE Washington DC 2549 Re: Online Originals, Inc. Preliminary Information Statement on Schedule 14C Filed June 25, 2010 File No. 000-53230 Dear Ms. Woo: We received your letter dated June 28, 2010. We have

LETTER

June 28, 2010 Shari Sookarookoff President and Chief Executive Officer Online Originals, Inc.

PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Reg.ss.240.14c-101 Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [] Definitive Information Statement ONL

SC 13D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sun River Energy, Inc.

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 24, 2010 ONLINE ORIGINALS, INC. - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction (Commission File (IRS Employer of incorporation) Number) I

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2010 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ON

10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED NOVEMBER 30, 2009 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE ORI

NT 10-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number-0-27485 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [] Form 11-K [] Form 20-F [] Form 10-Q [] Form N-SAR For Period Ended: November 30, 2009 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Repor

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2009 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLI

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2009 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 30, 2009 ONLINE ORIGINALS, INC. (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction of (Commission File (IRS Employer incorporation) Number) Id

LETTER

Mail Stop 4561 June 9, 2009 Ms. Shari Sookarookoff President and Chief Executive Officer Online Originals, Inc. 57113-2020 Sherwood Drive Sherwood Park, Alberta T8A 3H9 Canada Re: Online Originals, Inc. Form 10-K For Fiscal Year Ended November 30, 2008, as amended Filed March 10, 2009 File No. 000-54230 Dear Ms. Sookarookoff: We have completed our review of the above referenced filings and have no

CORRESP

Online Originals, Inc. 57113-2020 Sherwood Drive Sherwood Park, Alberta T8A 3H9 Canada May 26, 2009 Mr. Stephen G. Krikorian Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Re: Online Originals, Inc. Form 10K for fiscal year ended November 30, 2008 File No. 000-54230 Dear Mr. Krikorian: In response to your comment letter dated March 23, 2009, we hereby provide, in writing,

10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT #1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-13

CORRESP

Michael A. Littman Attorney at Law 7609 Ralston Road Arvada, CO 80002 (303) 422-8127 Fax (303) 431-1567 May 26, 2009 Mr. Stephen G. Krikorian Securities & Exchange Commission Accounting Branch 100 F Street, NW Washington, DC 20549-0405 Re: Online Originals, Inc. Form 10-K for fiscal year ended November 30, 2008 Filed March 10, 2009 File No. 000-54230 Dear Mr. Krikorian: In response to your comment

LETTER

Mail Stop 4561 May 18, 2009 Ms. Shari Sookarookoff President and Chief Executive Officer Online Originals, Inc. 57113-2020 Sherwood Drive Sherwood Park, Alberta T8A 3H9 Canada Re: Online Originals, Inc. Form 10-K For Fiscal Year Ended November 30, 2008 Filed March 10, 2009 File No. 000-54230 Dear Ms. Sookarookoff: We issued comments to you on the above captioned filing on March 23, 2009. As of the

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2009 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ON

NT 10-Q

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number - 333-133347 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 11-K [] Form 20-F [] Form 10-K [] Form N-SAR For Period Ended: February 28, 2009 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition R

LETTER

Mail Stop 4561 March 23, 2009 Ms. Shari Sookarookoff President and Chief Executive Officer Online Originals, Inc. 57113-2020 Sherwood Drive Sherwood Park, Alberta T8A 3H9 Canada Re: Online Originals, Inc. Form 10-K For Fiscal Year Ended November 30, 2008 Filed March 10, 2009 File No. 000-54230 Dear Ms. Sookarookoff: We have reviewed the above-referenced filing and have the following comment. Pleas

10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE ORI

NT 10-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number - 333-133347 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [] Form 11-K [] Form 20-F [] Form 10-Q [] Form N-SAR For Period Ended: November 30, 2008 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition

10QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended August 31, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE ORIG

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 12, 2008 ONLINE ORIGINALS, INC. (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction (Commission File (IRS Employer of incorporation) Numbe

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 29, 2008 ONLINE ORIGINALS, INC. - (Exact name of registrant as specified in its charter) Nevada 333-133347 98-0479983 - - - - (State or other jurisdiction of (Commission File (IRS Employer Identification incorp

10QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended May 31, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE ORIGINA

8-A12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Online Originals, Inc.

10QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended February 29, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE OR

10KSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2007 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE O

NT 10-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number - 333-133347 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [] Form 11-K [] Form 20-F [] Form 10-Q [] Form N-SAR For Period Ended: November 30, 2007 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition

10QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended August 31, 2007 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE ORIG

NT 10-Q

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number - 333-133347 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR For Period Ended: August 31, 2007 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Re

10QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended May 31, 2007 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE ORIGINA

10QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended February 28, 2007 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE ORI

10KSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2006 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-133347 ONLINE OR

10QSB

As filed with the Securities and Exchange Commission on October 13, 2006 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

10QSB

As filed with the Securities and Exchange Commission on June 26, 2006 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SB-2

As filed with the Securities and Exchange Commission on April , 2006 Registration No.